SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers

BMC Medical Genetics

Volumn 16, Issue 1, 2015, Pages

  Okamoto, Kanako ^a   Tsunematsu, Ryosuke ^a,c   Tahira, Tomoko ^b   Sonoda, Kenzo ^a   Asanoma, Kazuo ^a   Yagi, Hiroshi ^a   Yoneda, Tomoko ^a   Hayashi, Kenshi ^b   Wake, Norio ^b   Kato, Kiyoko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Department of Obstetrics and Gynecology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MDM2; TRANSCRIPTION FACTOR SP1; LUCIFERASE; MDM2 PROTEIN, HUMAN; PRIMER DNA;

ADULT; AGED; ALLELE SPECIFIC EXPRESSION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER RISK; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; DNA SEQUENCE; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN TISSUE; MDM2 GENE; MIDDLE AGED; NONHUMAN; PROMOTER REGION; PROTEIN DNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; SNP55; VERY ELDERLY; BINDING SITE; ENDOMETRIUM TUMOR; GENETICS; GENOTYPING TECHNIQUE; IMMUNOHISTOCHEMISTRY; METABOLISM; PLASMID; WESTERN BLOTTING;

BINDING SITES; BLOTTING, WESTERN; DNA PRIMERS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENOTYPING TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; LUCIFERASES; NF-KAPPA B P50 SUBUNIT; PLASMIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 84939512810     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/s12881-015-0216-8     Document Type: Article

References (74)

1. Adams PD. Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell. 2009;36(1):2-14.
2. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10(1):51-7.
3. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547-56.
4. Reddel RR. The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 2000;21(3):477-84.
5. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2005;26(5):867-74.
6. Lleonart ME, Artero-Castro A, Kondoh H. Senescence induction; a possible cancer therapy. Mol Cancer. 2009;8:3.
7. Tan P. Germline polymorphisms as modulators of cancer phenotypes. BMC Med. 2008;6:27.
8. Johnson NA, Porter AH. Rapid speciation via parallel, directional selection on regulatory genetic pathways. J Theor Biol. 2000;205(4):527-42.
9. Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, Giardiello FM, et al. Small changes in expression affect predisposition to tumorigenesis. Nat Genet. 2002;30(1):25-6.
10. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106(23):9362-7.
11. Manolio TA, Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med. 2009;60:443-56.
12. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. Allelic variation in human gene expression. Science (New York, NY). 2002;297(5584):1143.
13. Knight JC. Allele-specific gene expression uncovered. Trends Gen. 2004;20(3):113-6.
14. Pastinen T. Genome-wide allele-specific analysis: insights into regulatory variation. Nat Rev Genet. 2010;11(8):533-8.
15. Buckland PR. Allele-specific gene expression differences in humans. Hum Mol Genet. 2004;13 Spec No 2:R255-60.
16. Lee MP. Allele-specific gene expression and epigenetic modifications and their application to understanding inheritance and cancer. Biochim Biophys Acta. 2012;1819(7):739-42.
17. Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH, et al. Allelic variation in gene expression is common in the human genome. Genome Res. 2003;13(8):1855-62.
18. Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR, et al. Functional analysis of human promoter polymorphisms. Hum Mol Genet. 2003;12(18):2249-54.
19. Pant PV, Tao H, Beilharz EJ, Ballinger DG, Cox DR, Frazer KA. Analysis of allelic differential expression in human white blood cells. Genome Res. 2006;16(3):331-9.
20. Heap GA, Yang JH, Downes K, Healy BC, Hunt KA, Bockett N, et al. Genome-wide analysis of allelic expression imbalance in human primary cells by high-throughput transcriptome resequencing. Hum Mol Genet. 2010;19(1):122-34.
21. Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, et al. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science (New York, NY). 2008;321(5894):1361-5.
22. Abdollahi MR, Lewis RM, Gaunt TR, Cumming DV, Rodriguez S, Rose-Zerilli M, et al. Quantitated transcript haplotypes (QTH) of AGTR1, reduced abundance of mRNA haplotypes containing 1166C (rs5186:A > C), and relevance to metabolic syndrome traits. Hum Mutat. 2007;28(4):365-73.
23. Grigorova M, Punab M, Poolamets O, Kelgo P, Ausmees K, Korrovits P, et al. Increased Prevalance of the -211 T allele of follicle stimulating hormone (FSH) beta subunit promoter polymorphism and lower serum FSH in infertile men. J Clin Endocrinol Metabol. 2010;95(1):100-8.
24. Grigorova M, Punab M, Ausmees K, Laan M. FSHB promoter polymorphism within evolutionary conserved element is associated with serum FSH level in men. Hum Reprod. 2008;23(9):2160-6.
25. Chen X, Weaver J, Bove BA, Vanderveer LA, Weil SC, Miron A, et al. Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum Mol Genet. 2008;17(9):1336-48.
26. Popat S, Stone J, Houlston RS. Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer. Cancer Genet Cytogenet. 2003;145(1):70-3.
27. Pinheiro H, Bordeira-Carrico R, Seixas S, Carvalho J, Senz J, Oliveira P, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet. 2010;19(5):943-52.
28. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591-602.
29. Wang M, Zhang Z, Zhu H, Fu G, Wang S, Wu D, et al. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res. 2008;14(11):3633-40.
30. Knappskog S, Bjornslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell. 2011;19(2):273-82.
31. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991;10(6):1565-9.
32. Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene. 1997;15(9):1001-10.
33. Momand J, Wu HH, Dasgupta G. MDM2--master regulator of the p53 tumor suppressor protein. Gene. 2000;242(1-2):15-29.
34. Juven-Gershon T, Oren M. Mdm2: the ups and downs. Mol Med. 1999;5(2):71-83.
35. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13(1):49-58.
36. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358(6381):80-3.
37. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53(10 Suppl):2231-4.
38. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453-9.
39. Bueso-Ramos CE, Yang Y, de Leon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82(9):2617-23.
40. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res. 2001;61(20):7642-6.
41. Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 2002;94(23):1803-6.
42. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 2001;61(7):3212-9.
43. Hori M, Shimazaki J, Inagawa S, Itabashi M. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat. 2002;71(1):77-83.
44. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene. 1993;8(12):3411-6.
45. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7(7A):1126-32.
46. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 1995;23(14):2584-92.
47. Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Romundstad P, et al. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer (Oxford, England: 1990). 2012;48(13):1988-96.
48. Knappskog S, Lonning PE. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget. 2011;2(3):251-8.
49. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65(13):5481-4.
50. Knappskog S, Gansmo LB, Romundstad P, Bjornslett M, Trovik J, Sommerfelt-Pettersen J, et al. MDM2 promoter SNP344T > A (rs1196333) status does not affect cancer risk. PLoS ONE. 2012;7(4), e36263.
51. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007;104(3):660-4.
52. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 2006;24(27):4434-40.
53. Onat OE, Tez M, Ozcelik T, Toruner GA. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res. 2006;26(5A):3473-5.
54. Post SM, Pant V, Abbas H, Quintas-Cardama A. Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma. Oncotarget. 2010;1(3):168-74.
55. Paulin FE, O'Neill M, McGregor G, Cassidy A, Ashfield A, Ali CW, et al. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer. 2008;8:281.
56. Wo X, Han D, Sun H, Liu Y, Meng X, Bai J, et al. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. J Gen Genomics = Yi chuan xue bao. 2011;38(8):341-50.
57. El Hallani S, Marie Y, Idbaih A, Rodero M, Boisselier B, Laigle-Donadey F, et al. No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J Neuro-Oncol. 2007;85(3):241-4.
58. Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Forsti A, et al. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol. 2007;157(2):375-7.
59. Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res. 2006;26(6C):4975-7.
60. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28(11):2262-7.
61. Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 2006;240(2):195-7.
62. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomark Prev. 2008;17(4):983-6.
63. Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22(2):49-54.
64. Li Y, Zhao H, Sun L, Huang L, Yang Q, Kong B. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell. 2011;24(2):57-64.
65. Zajac A, Stachowiak G, Pertynski T, Romanowicz H, Wilczynski J, Smolarz B. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Pol J Pathol. 2012;63(4):278-83.
66. Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, et al. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep. 2013;30(1):25-34.
67. Tahira T, Kukita Y, Higasa K, Okazaki Y, Yoshinaga A, Hayashi K. Estimation of SNP allele frequencies by SSCP analysis of pooled DNA. Methods Mol Biol (Clifton, NJ). 2009;578:193-207.
68. Hirano F, Tanaka H, Hirano Y, Hiramoto M, Handa H, Makino I, et al. Functional interference of Sp1 and NF-kappaB through the same DNA binding site. Mol Cell Biol. 1998;18(3):1266-74.
69. Kato K, Ueoka Y, Hachiya T, Nishida J, Wake N. Contribution of enhanced transcriptional activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation. Oncogene. 1997;15(25):3037-46.
70. Kato K, Horiuchi S, Takahashi A, Ueoka Y, Arima T, Matsuda T, et al. Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway. J Biol Chem. 2002;277(13):11217-24.
71. Suga S, Kato K, Ohgami T, Yamayoshi A, Adachi S, Asanoma K, et al. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol. 2007;105(2):341-50.
72. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010;18(3):220-30.
73. Tong X, Yin L, Washington R, Rosenberg DW, Giardina C. The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem. 2004;265(1-2):171-83.
74. Pereira SG, Oakley F. Nuclear factor-kappaB1: regulation and function. Int J Biochem Cell Biol. 2008;40(8):1425-30.